User Image

Dr. Hari Goyal

Specialization - Hematologist

Department - Hematology

Designation - Director

Works at - Artemis Hospital

Gurgaon, India

Career Profile

With 23 years of experience, Dr. Hari Goyal is one of India's top Medical Oncologists. He has worked in some of India's best cancer centers. Many prominent oncologists who have become industry pioneers have benefited from his influence. Through his clinical trial research, he has contributed to the field of cancer chemotherapy. In this way, he created drugs that mitigate the side effects of anti-cancer chemotherapy. His responsibilities include patient care and clinical research. He has numerous publications in national and international medical journals to his name. He was also a participant in an FDA-audited trial in the United States.

Education & Training

  • MBBS from Sardar Patel Medical College, Bikaner in 1993
  • MD (Internal Medicine) from SMS Hospital, Jaipur in 1997
  • Professional Diploma in Clinical Research in 2008
  • DM (Oncology) from AIIMS, New Delhi in 2003

Work & Experience

  • Consultant at Tata Memorial Hospital
  • Consultant at Rajiv Gandhi Cancer Hospital
  • Consultant at Batra hospital, New Delhi
  • Consultant at AIIMS, Delhi
  • Consultant at Action Cancer Hospital, New Delhi
  • Consultant at BL Kapoor Hospital, New Delhi
Clinical Focus
  • Chemotherapy
  • Acute Lymphocytic Leukemia - ALL in Adults
  • Breast Biopsy
  • Hairy Cell Leukemia - HCL
Awards
  • Triveni Ratna Award is given by Member of Parliament
  • Shri Mahabal Mishra Unnat Bharat Seva given by Union Minister of Agriculture at Parliament
  • Annexe Recipient of many awards at local functions across India
Research and Publications
  • Clinical research associate in protocol 94CE 32 .Phase III comparative study of combination treatment with TLC D99 liposomal doxorubicin and cyclophosphamide and doxorubicin in metastatic breast cancer.
  • A Multicentric, open label phase III clinical trial to evaluate the safety of filgrastim in cancer patients with grade 3 or 4 chemotherapy induced neutropenia.
  • Organizing secretary, 4th international seminar on psychosocial oncology, new delhi ,april 1999.
  • TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer.
  • SB3-G31-BC: A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptinu00ae in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting.
  • A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer under fed cond.
  • A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients.

Hospitals

Book an Appointment